CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

| More on:
Buy, hold and sell ratings written on signs on a wooden pole.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are up 0.3% at $261.87 today, shaking off the broader market sell-down. 

This sees the company with a market cap of almost $127 billion, making it the third largest stock on the ASX.

Over the past year, however, shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock have trailed the benchmark, sliding 9%, while the ASX 200 has gained 8%.

Though those losses were somewhat moderated by the $4.25 a share in unfranked dividends CSL paid out (or shortly will pay out) over the year.

But with CSL shares continuing to struggle in 2025, is the biotech stock one to buy, sell, or hold onto?

Below, we look at the investment case for each option (courtesy of The Bull).

Time to sell CSL shares?

If you ask three different analysts what their outlook is for CSL shares, you may well get three different replies.

With that in mind, Daylight Financial Group's Elio D'Amato has a rather bearish outlook on the stock.

"The biotechnology giant disappointed the market with its first half result in fiscal year 2025," said D'Amato, who has a sell recommendation on CSL stock.

D'Amato noted:

Revenue at the company's vaccine division Seqirus was down 9% due to low immunisation rates, particularly in the US. The plasma collection division CSL Behring remains the key profit driver.

The company is expected to meet full year net profit after tax and amortisation of $3.2 billion to $3.3 billion at constant currency.

Addressing the dawdling share price, D'Amato concluded:

With limited near-term catalysts amid concerns about the outlook for Seqirus, some investors may see better opportunities elsewhere, particularly as the share price has done nothing for years.

Know when to hold 'em

Medallion Financial Group's Stuart Bromley has a more optimistic take on CSL shares.

"The share price of this global healthcare powerhouse was recently punished after posting what investors considered was an underwhelming interim result in fiscal year 2025," said Bromley, who has a hold recommendation on the stock.

Noting that he's "encouraged by CSL's longer-term prospects", Bromley added:

The plasma business Behring performed well and is positioned for growth after rolling out 220 new collection centres. The vaccines business in the first half was weak, but we expect a stronger second half as Northern Hemisphere revenues flow to the business.

The bullish case for CSL shares

Family Financial Solutions' Jabin Hallihan believes the retrace in CSL shares makes the ASX 200 biotech stock attractive at current levels.

"The company's share price recently hit a 52-week low, making it an attractive entry point, in our view," said Hallihan, who has a buy recommendation on the stock.

According to Hallihan:

Despite mixed half year results in fiscal year 2025, the company lifted net profit after tax by 7% at constant currency. A strong performance from CSL Behring amid a dividend increase in Australian currency of 16% on the prior corresponding period highlight its potential.

The company is positioned to deliver annualised double-digit earnings growth in the medium term.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should you buy the dip on the CSL share price?

Has the market sell-off created an opportunity to buy this mega ASX 200 blue chip at an attractive price?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 136% in a year, why is this ASX 200 share slipping on Wednesday?

The high-performing ASX 200 share is expanding its product pipeline.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

This ASX 200 healthcare share is sinking 9% on CEO exit

Investors are selling off this stock on Tuesday. Here's what you need to know.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the CSL share price falling on Monday?

The ASX 200 biotech stock has lost 9% of its value since the start of the new year.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are Sonic Healthcare or CSL shares a better buy?

Which of these healthcare giants is a better buy?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Dividend Investing

Hoping to bag the boosted dividend from CSL shares? Here's your deadline…

The ASX 200 biotech is rewarding investors with a 9% higher interim dividend this year.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares rated as top buys

Are these two names healthy choices for your portfolio? Let's see.

Read more »